Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Tech·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

19% 確率
Polymarket

$10,135 Vol.

19% 確率
Polymarket

$10,135 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months. Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$10,135
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader sentiment heavily favors “No” at 80.5% because the October 2024 research collaboration remains strictly an evaluation-stage agreement rather than a commercial license.** Under that deal, Eli Lilly received only a non-exclusive, worldwide license for internal R&D on applying Peptron’s ultrasonic spray-dried PLGA microsphere SmartDepot platform to select peptides, with any future commercial deal explicitly described as possible but not guaranteed. The original 14-month term was extended to a maximum of 24 months, placing the evaluation window through roughly October 2026, yet no binding technology-transfer or commercialization agreement has been announced in the intervening 20 months. Recent developments reinforce caution. Lilly’s June 2025 and 2026 expansions of its lipid-based injectable partnership with Camurus for overlapping therapeutic areas (including amylin agonists) triggered sharp share-price drops at Peptron, though the Korean firm reiterated that the platforms target different compounds and that SmartDepot evaluation continues on schedule. Preclinical data on PT403 (SmartDepot semaglutide) and safety signals have been shared, but these remain early-stage and have not triggered a commercial commitment. With only weeks left before the October 7 resolution and no reported progress toward a definitive license, capital-backed traders view a last-minute announcement as unlikely, producing the current strong “No” consensus.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$10,135
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

外部リンクに注意してください。

よくある質問

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」はPolymarket上の予測市場で、トレーダーがこのイベントが起こるかどうかに基づいて「はい」または「いいえ」のシェアを売買します。コミュニティによる現在の確率は「Yes」に対して19%です。例えば、「はい」が19¢で取引されている場合、市場はこのイベントが発生する確率を19%と集合的に評価しています。これらのオッズはトレーダーが新しい展開や情報に反応するにつれて継続的に変化します。正しい結果のシェアは市場決済時に各$1で引き換え可能です。

本日現在、「Eli Lilly licenses Peptron’s SmartDepot by October 7?」は$10.1Kの総取引量を生み出しています（May 5, 2026のマーケット開始以来）。この取引活動レベルはPolymarketコミュニティの強い関与を反映し、現在のオッズが幅広い市場参加者によって形成されていることを保証します。このページで直接、ライブの価格変動を追跡し、任意の結果で取引できます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」で取引するには、答えが「はい」か「いいえ」かを選ぶだけです。各側には市場の暗示確率を反映する現在の価格があります。金額を入力して「取引」をクリックします。「はい」のシェアを購入し、結果が「はい」と決まった場合、各シェアは$1を支払います。「いいえ」と決まった場合、「はい」のシェアは$0を支払います。決済前にいつでもシェアを売却して利益を確定したり、損失を抑えたりすることもできます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の現在の確率は「Yes」に対して19%です。これはPolymarketコミュニティがこのイベントの発生確率を19%と現在評価していることを意味します。これらのオッズは実際の取引に基づいてリアルタイムで更新され、市場の期待を継続的に反映するシグナルを提供します。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の決済ルールは、各結果が勝者と宣言されるために何が起こる必要があるかを正確に定義しています。これには結果を決定するために使用される公式データソースも含まれます。このページのコメント上にある「ルール」セクションで完全な決済基準を確認できます。取引前にルールを注意深く読むことをお勧めします。